Boehringer Ingelheim’s Ofev secures FDA approval for SSc-ILD

This article was originally published here

Ofev has been indicated for slowing the rate of decline in pulmonary function in adult patients with SSc-ILD, which makes it the first FDA-approved treatment for the rare

The post Boehringer Ingelheim’s Ofev secures FDA approval for SSc-ILD appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply